Loading
CCNT1 (Cyclin-T1) is a protein that switches other genes on and off. In the public catalogues it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II). Required to activate the protein kinase activity of CDK9: acts by mediating formation of liquid-liquid phase separation (LLPS) that enhances binding of P-TEFb to the CTD of RNA Pol II. Serves as an essential cofactor for Tat, by promoting RNA Pol II activation, allowing transcription of viral genes.
IntOGen calls it a driver in 1 cohort (0 activating, 0 loss-of-function), covering Acute Myeloid Leukaemia.
In plain words · CCNT1 (Cyclin-T1) is a protein that switches other genes on and off. In the public catalogues it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
CCNT1 (Cyclin-T1) is a protein that switches other genes on and off. In the public catalogues it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II).
No product in this corpus aims at CCNT1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
First described 1998. Earliest sequence paper UniProt cites for the protein: Wei et al, Cell, 1998, "A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA". Source.
Sources: HGNC HGNC:1599 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O60563 (protein name, function text, keywords and locations (REST API)); IntOGen CCNT1 (driver in 1 cohort (Act 0, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II). Required to activate the protein kinase activity of CDK9: acts by mediating formation of liquid-liquid phase separation (LLPS) that enhances binding of P-TEFb to the CTD of RNA Pol II. Serves as an essential cofactor for Tat, by promoting RNA Pol II activation, allowing transcription of viral genes. Location: Nucleus (UniProt). Locus 12q13.11-q13.12 (HGNC).
Query for this target: (TITLE:"CCNT1" OR ABSTRACT:"CCNT1" OR TITLE:"cyclin T1" OR ABSTRACT:"cyclin T1" OR TITLE:"Cyclin-T1" OR ABSTRACT:"Cyclin-T1" OR TITLE:"CYCT1" OR ABSTRACT:"CYCT1" OR TITLE:"HIVE1" OR ABSTRACT:"HIVE1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCNT1, not a curated reading list.